Armata Pharmaceuticals Q3 EPS $(0.86) Misses $(0.31) Estimate, Sales $1.23M Beat $950.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Armata Pharmaceuticals (AMEX:ARMP) reported a Q3 EPS loss of $(0.86), significantly missing the $(0.31) estimate, representing a 258.33% increase in losses year-over-year. However, sales of $1.23M exceeded expectations by 28.95%, despite being an 8.45% decrease from the previous year.
November 14, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Armata Pharmaceuticals reported a larger-than-expected Q3 EPS loss of $(0.86) but exceeded sales estimates with $1.23M in revenue.
The significant miss on EPS is likely to negatively impact investor sentiment in the short term, overshadowing the sales beat. The magnitude of the EPS miss suggests underlying challenges that may concern investors, potentially leading to a decrease in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100